Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study
Conclusions:
According to these analyses, and in line with other analyses of pertuzumab and trastuzumab in the neoadjuvant setting, we conclude that HER2 expression remains the only marker suitable for patient selection for this regimen at present.Trial registration: The TRYPHAENA study was registered with ClinicalTrials.gov, NCT00976989, on September 14 2009.
Source: Breast Cancer Research - Category: Cancer & Oncology Authors: Andreas SchneeweissStephen ChiaRoberto HeggChristoph TauschRahul DebJayantha RatnayakeVirginia McNallyGraham RossAstrid KiermaierJavier Cortés Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Herceptin | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study